Israeli biomedical company BioCell, which develops treatments for cancer, reports positive preliminary findings in trials conducted with BC-819. The drug, developed for treatment of pancreatic cancer, has registered a 66 percent success rate in stopping the diseases progress and even reducing tumor size. The trial’s final results will be published in the beginning of 2013.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments